Clinical Data's sale of its genomic services unit to Beckman Coulter will not affect its pharmacogenomics efforts, but will enable it to better focus on its drug development and biomarker discovery programs, the company says.

Beckman Coulter's acquisition of Clinical Data's Cogenics business for around $17 million, announced this spring, "will have no impact on our focus as a pharmacogenomics company," according to Clinical Data CEO Drew Fromkin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.